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Poster Session II S257Background: Palifermin at 60ug/kg/dose, decreases the severity of
oral mucositis (OM) in adults with hematologic malignancies
undergoing SCT. Currently there is no proven therapy to decrease
severe OM in pediatric subjects receiving chemotherapy +/- radia-
tion for SCT. Reducing severe OM in pediatrics should decrease
infection, pain, and enteral nutrition use and improve outcome
following SCT.
Study Design: Phase 1 dose escalation study of palifermin to deter-
mine the safety and dosing for pediatric subjects with acute leuke-
mia’s undergoing myeloablative allogeneic SCT.
Conditioning regimen: Palifermin SCT Days -10 to -8 and 0 to
+2, 1200 cGy (200 cGy  6 fractions) TBI, etoposide 1500 mg/m2,
and cyclophosphamide 120 mg/kg.
24 patients have been enrolled. Three age groups studied: 1 to 2, 3
to 11, and 12 to 16 years old. Three dose levels studied: 40, 60, and
80ug/kg/day. All groups have completed enrollment except 1 to 2
year group at 80ug/kg/dose.
Results: Safety data-no deaths, dose limiting toxicities (DLT), or
treatment related serious adverse events (SAE’s). The most common
adverse event related to palifermin was rash, 6/24 subjects (4/6 in the
80, and 1/9 in the 60 and 40 ug/kg/dose groups), followed by puritis,
3/24 subjects (2/6 in the 80 and 1/9 in the 60 ug/kg/dose group).
Pharmacokinetic data was not sufficient to show if linear pharma-
cokinetics occurs or if age impacts the pharmacokinetics in pediat-
rics. No accumulation of palifermin after 3 consecutive daily doses
occurred. Antibodies to palifermin were not seen on blood samples
obtained on SCT day -10, +30 and +100. OM grades 3 and 4 were
seen in 3/9 subjects receiving 40, 5/9 receiving 60, and 0/6 receiving
80 ug/kg/dose. 6/24 subjects had . grade 2 graft versus host
disease.
Conclusion: 1. No DLT’s and no SAE’S in any of the completed
age/dose groups. The 1 to 2 year group continues to enroll at 80
ug/kg/dose with no DLT’s or SAE’’s in the 40 and 60 ug/kg/dose
levels.
2. No grade 3/4 OM occurred in the 80 ug/kg/dose, suggesting
a relationship between palifermin dosing and severity of OM.
3. The data review team recommended a palifermin dose of 80 ug/
kg/dose for 3 to 11 and 12 to 16 year old age groups for future effi-
cacy studies. The incidence of OM was less and no SAE’s at this dose,
however the number of patients this is based on is small.
4. Recommendations for future efficacy studies for the 1 to 2 age
group will be made when the 80 ug/kg dose is completed.269
RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN
(RBPI21) FOR ENDOTOXIN (LIPOPOLYSACCHARIDE, LPS) NEUTRALIZA-
TION DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT): PHASE I/II CLINICAL TRIAL RESULTS
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2 Children’s Hospital, Boston, MA; 3 Beth Israel Deaconess Medical Center,
Boston, MA; 4 Children’s Hospital of Philadelphia, PA; 5 Xoma (US) LLC,
Berkeley, CA; 6 Spectral Diagnostics, Toronto, ON, Canada; 7 Brigham
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Mucosal barrier injury caused by HSCT chemoradiotherapy
conditioning leads to translocation of bacteria and bacterial prod-
ucts, including LPS-bearing bacteria and free LPS, into the sys-
temic circulation. LPS signaling through its TLR4 receptor
results in inflammatory cytokine release and resulting hypotension,
fever, coagulopathy and end organ dysfunction. In allogeneic mu-
rine HSCT models, prior immunization to LPS, blockade of
LPS:TLR4 signaling and use of LPS hyporesponsive mice all de-
crease HSCT morbidity and mortality, particularly acute GVHD
and interstitial pneumonia. As humans are both very LPS sensitive
and known to be endotoxemic early peri-HSCT, we initiated
a cohort dose escalation Phase I/II study of rBPI21, a recombinant
fragment of a neutrophil granule cationic protein with potent LPS-
neutralizing activity in vivo, in patients (pts) undergoing conven-
tional allogeneic myeloablative HSCT with sibling or unrelatedPBSC or BM. The first cohort (CHT1) filled with 6 pts aged
17-65 (median 54 yrs). Pts received 4 mg/kg bolus IV rBPI21 Day
(D) -1 followed by 6 mg/kg/D continuous IV for 3 D. No severe
adverse events (AE) were seen. A prospective observational
HSCT study (OBS) enrolled 13 pts aged 35-59 (median 48) meet-
ing trial eligibility who gave blood samples on the same schedule.
All CHT1 AE through discharge were # Grade (Gr) 3. 10 Gr 3
AEs were seen: mucositis (3), infections (ID,5), and hypertension
(2). In OBS, pts had 23 Gr 3, 7 Gr 4 and 3 Gr 5 AE – Gr 3: mu-
cositis (7), ID (10), hyper/hypotension (2), liver (3), renal (1); Gr
4:cardiac (3), mucositis (2), liver (1), ID (1); Gr 5: 1 each VOD,
ARDS, DAH. Time to engraftment was the same. LPS, by endo-
toxin activity assay (EAA, Spectral Diagnostics), and cytokine levels
were drawn before conditioning, D -1 (pre rBPI21), D0, D2 (end of
rBPI21) and weekly to D21. CHT1 EAA levels were\OBS at all
timepoints, p \ .033 at D2. IL6 levels, reflective of bioactive
LPS, increased less from baseline in CHT1 at all timepoints vs
OBS, p\ .014 D 14. Other assays are in process. The trial closed
after CHT1 due to rBPI21 supply issues. However, this first human
trial of LPS neutralization during HSCT supports feasibility and
tolerability. There is encouraging evidence of bioactivity, and pos-
sible decreased HSCT morbidity, at a biologically suboptimal dose.
Additional studies with this or similar LPS antagonists should be
performed to fully evaluate potential efficacy in attenuating
HSCT toxicity including GVHD.270
CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE IN HEMATAPOETIC
STEM CELL TRANSPLANTATION RECIPIENTS
Trifilio, S., Pi, J., Mehta, J. Northwestern Memorial Hospital, Chicago,
IL
Clostridium Difficile-associated disease(CDAD) is a source of
morbidity and mortality for hematapoetic stem cell transplantation
recipients(HSCT). Risk factors for the development of CDAD are
largely unknown. We retrospectively reviewed 822 HSCT recipient
charts for the incidence of CDAD and evaluated risk factors and out-
comes associated with CDAD.
Methods: 822 consecutive HSCT recipients(615 autologous/207 al-
logeneic) from Northwestern Memorial Hospital (NMH)between
2004-08 were reviewed. CDAD was evaluated from the day of admis-
sion until dischage following HSCT. All patients received acyclovir,
ciprofloxacin and an azole as prophylaxis. Cefepime(CEF) or Piper-
acillin/Tazobactam(P/T) were initiated for neutropenic(NTP) fe-
ver. Due to NMH policy changes, 50% of patients received a low
microbial diet, while 50% did not. Bivariate analysis was used to eval-
uate the correlation between CDAD and dependent variables. This
study was approved by NMH IRB.
Results: Results for 83 patients identified with CDAD are listed in
table 1.There was a significant difference in the incidence of
CDAD between autologous and allogeneic HSCT 14.5% vs
8.5%: p5 .023)respectively. There was no association between
CDAD and age, sex, diagnosis, or conditioning regimen(except
more CDAD patients received RIST:p5 .027). Median time to oc-
currence of CDAD was 8days post-HSCT. Time to engraftment
was similar for CDAD and non-CDAD HSCT recipients(12 and
11 days respectively). A significant correlation was found between
patients who were colonized with VRE and subsequent develop-
ment of CDAD(p5 .0014). Patients who were fed a low microbial
diet(auto/allo matched) were also at increased risk for CDAD (51/
411 vs 32/411:p5 .05). Neither CEF nor P/T treatment was asso-
ciated with CDAD. Vancomycin use was associated with increased
risk for CDAD although patients were initiated only 1 day(median)
prior to CDAD. No correlation was found between patients who
developed NTP fever during HSCT and CDAD and the number
of co-infections was similar in CDAD and non-CDAD patients.
11/30 allo HSCT recipients who had CDAD developed Grade 3-
4 GI GVH within 30d of CDAD treatment. Overall inpatient mor-
tality was significantly greater for patients with CDAD(7/82 vs 25/
740: p5 .032)
Conclusion: CDAD poses a risk for increased morbidity and mor-
tality for recipients of HSCT. Identification and correction of
S258 Poster Session IIpotentially reversibe risk factors could lessen the potentially disas-
trous results associated with CDAD.
Clostridium Difficile associated Disease
Characteristic CDAD postive CDAD negative p-valueNumber 83 739
age(range) 60(21-74) 56(18-78) .0687
sex(male/female) 37 444/295 0.410
Allo HSCT vs 30 177
Auto HSCT 53 562 .0232
Cefepime 64/83 496/739 .0831
Pip/Tazo 13/83 134/739 .651
Vancomycin 58/83 397/739 .0051
VRE surveillance positiv 29/83 140/739 .0014
Mortality 7/83 25/739 .0345271
ADENOVIRUS (ADV) INFECTION IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) RECIPIENTS IS A MAJOR INDEPENDENT
FACTOR FOR SIGNIFICANTLY INCREASING THE RISK OF TREATMENT RE-
LATED MORTALITY
El-Mallawany, N.K.1, George, D.1, Jin, Z.2, Della-Latta, P.3,
Satwani, P.1, Garvin, J.H.1, Bradley, M.B.1, Bhatia, M.1, van de
Ven, C.1, Morris, E.1, Schwartz, J.3, Cairo, M.S.1,3,4 1 Morgan Stanley
Children’s Hospital, New York-Presbyterian, Columbia University, NY;
2 Columbia University, New York, NY; 3 Columbia University, New
York, NY; 4 Columbia University, New York, NY
Background: ADV infection is an important cause of morbidity
following alloSCT in children, and the attributable mortality of
disseminated ADV in pediatric alloSCT recipients may exceed
80%. We sought to determine the incidence, risk factors, and
associated outcomes of ADV infection in pediatric AlloSCT re-
cipients.
Methods: We analyzed 123 consecutive pediatric AlloSCT recipi-
ents. Conditioning regimens were diverse; 59 (48%) received
reduced toxicity conditioning while 64 (52%) received a myeloabla-
tive regimen. Conditioning regimens included Alemtuzumab or
ATG in 24 (19.5%) and 65 (52.8%) patients respectively. GVHD
prophylaxis (tacrolimus and mycophenolate mofetil) and CMV pro-
phylaxis (alternating foscarnet and ganciclovir) were as previously
described (Osunkwo/Cairo et al, BBMT 2004; Shereck/Cairo et al,
PBC 2006). ADV was diagnosed by antigen detection or viral cul-
ture, and was defined by the isolation of virus with presence of cor-
relating clinical symptoms. Antigen detection was performed by
direct fluorescent assay from respiratory specimens and enzyme
immunoassay from stool.
Results: Age: median 9.5 (0.33–21 years), male/female: 71/52.
MFD 20%, MUD/UCBT 80%. Mean follow-up was 694 days.
The probability of developing ADV infection was 12.3% (CI95
6.0-18.6) and the median time to infection was 42 days (7-203
days). There were no statistically significant differences in proba-
bility of ADV infection in univariate analysis of risk factors includ-
ing donor source, use of ATG/Alemtuzumab, $ Grade II GVHD,
among others (age, diagnosis, conditioning regimen). The proba-
bility of overall survival (OS) for the entire cohort was 46.3%
(CI95 37.3-55.3). The probability of overall survival (OS) for pa-
tients that experienced ADV infection was 15.4% compared to
50% for those without ADV (p5 0.0286). In multivariate analysis,
several risk factors remained significant for an increased risk of
death including: ablative conditioning (HR 1.9), poor risk (HR
2.1), and most importantly, ADV infection (HR 3.15 [CI95 1.6-
6.18] p5 0.0009).
Conclusions: In this series of pediatric AlloSCT recipients, the de-
velopment of ADV infection was the leading multivariate predictor
of treatment-related mortality. Enhanced surveillance with ADV
PCR and identification of the risk factors associated with poor out-
comes from ADV infection may identify patients who could benefit
from pre-emptive therapeutic interventions including ADV-specific
cellular immunotherapies.272
ELEVATED SERUM LEPTIN LEVEL IN PATIENTS WITH PERSISTENT AN-
OREXIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLO-HSCT)
Kim, S.-W.1, Fuji, S.1, Fukuda, T.1, Mori, S.1, Kamiya, S.2, Furuta, K.3,
Yokoyama, H.1, Kurosawa, S.1, Saito, B.1, Kuwahara, S.2, Heike, Y.1,
Tanosaki, R.1, Takaue, Y.1 1 National Cancer Center Hospital, Tokyo, Ja-
pan; 2 National Cancer Center Hospital, Tokyo, Japan; 3 National Cancer
Center Hospital, Tokyo, Japan
Background: Gastrointestinal toxicities, infections and GVHD are
common events among patients who undergo allo-HSCT. Leptin
is a hypothalamic modulator of food intake, and is secreted mainly
from adipose tissue. Additionally, it has been reported that circulat-
ing leptin levels increase during infection and inflammation, in-
cluding with autoimmune diseases. To examine whether leptin
may play a pathophysiological role in the early phase of HSCT,
we measured the serum level of leptin for correlation with clinical
parameters.
Methods: The serum level of leptin was measured using the ELISA
method in 67 patients (35 male, 32 female) who received allo-HSCT
from April 2006 to October 2007. The median age of the patients
was 48 years (range, 17-64). Allo-HSCT (42 BM, 20 PB, 5 cord
blood; 45 unrelated, 22 related) for hematologic diseases (31 AML,
21 lymphoma, 7 ALL, 8 others) was performed using myeloablative
(19 BU/CY, 17 CY/TBI6CA) or reduced-intensity conditioning
(14 Flu/BU/ATG-F 5-10 mg/kg, 9 Flu/BU/2-4 Gy TBI, 8 2CdA
or Flu/BU). GVHD prophylaxis was TAC-based in 45 patients
(67%) and CSP-based in 22 patients (33%). Fifty-eight patients
(87%) also received short-term MTX. We defined persistent an-
orexia as oral intake of less than 50% the basal energy expenditure
after 4 weeks post-HSCT. Fat mass was also measured using an In-
Body S20 body composition analyzer (Biospace Co., Ltd., Seoul,
Korea).
Results: The median levels of serum leptin before the conditioning
regimen, and at 1, 2 and 4 weeks after HSCT were, respectively,
4.4 mg/dL, 9.4 mg/dL, 7.8 mg/dL and 7.1 mg/dL. There was a sig-
nificant correlation between the pre-HSCT leptin level and pre-
HSCT body mass (r5 0.34, P5 0.005). The pre-HSCT leptin level
was higher in females than in males (median 5.4 mg/dL v 3.4 mg/dL,
P5 0.04). Pre-HSCT fat mass was recorded in 60 patients, and this
was significantly correlated with the pre-HSCT leptin level
(r5 0.63, P\0.001). There were 29 patients with persistent an-
orexia, and patients whose leptin level increased after HSCT
(n5 38) tended to have a higher incidence of persistent anorexia
(68% v 41%, P5 0.046). There was no correlation between the in-
cidence of acute GVHD and either the pre-HSCT leptin level or the
increase in leptin.
Conclusions: This study suggests that the elevation of leptin could
be associated with persistent anorexia after allo-HSCT. It may be
possible to develop an effective intervention against anorexia by sup-
pressing this leptin elevation.273
CYCLOSPORINE AREA UNDER THE CURVE (AUC) IN CHILDREN UNDER-
GOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): LIM-
ITED SAMPLING STRATEGY (LSS)
Schechter, T.1, Teuffel, O.1, Gibson, P.1, Sung, L.1, Seto, W.2, Gassas, A.1,
Doyle, J.1, Dupuis, L.L.1,2 1 The Hospital for Sick Children, Toronto, ON,
Canada; 2 The Hospital for Sick Children, Toronto, ON, Canada
HSCT outcomes may be optimized by cyclosporine dose adjust-
ment according to systemic exposure (measured by AUC) rather
than trough concentration. We have developed LSSs for predicting
cyclosporine AUC after the initial IV dose in children undergoing
HSCT. The aim of this study was to validate the previously devel-
oped LSSs.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12 h as a 2-hour infusion and methotrexate/methylprednisolone
for acute GVHD prophylaxis were eligible. Cyclosporine AUC was
determined after the first dose and once weekly until engraftment us-
ing 9 concentration-time points.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
